Case-control study about the acceptance of Pegvaliase in Phenylketonuria

ConclusionPKU patients have reservations against an invasive subcutaneous treatment for their disease. This is mainly caused by the form of application by syringe and the potential harmful side effects. Only less than one-third of the patients in our cohort are willing to start treatment. Besides that, most PKU patients seem to have untapped potential for self-contained reduction of Phe-levels only by being focused on their diet.
Source: Molecular Genetics and Metabolism Reports - Category: Genetics & Stem Cells Source Type: research